Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315881 | 0.91 | MEN1 (0.52) | GPR119LMNAPOLBTHRBTP53 | |
| SCHEMBL8285418 | 0.77 | MEN1 (0.53) | GPR119LMNATHRBTP53GAA | |
| SCHEMBL8285133 | 0.76 | CACNB4 (0.46) | GPR119LMNATHRBTP53GAA | |
| SCHEMBL8255797 | 0.76 | MEN1 (0.52) | GPR119LMNATHRBTP53GAA | |
| SCHEMBL5212840 | 0.76 | BRD4 (0.57) | GPR119LMNATHRBTP53HPGDS | |
| SCHEMBL5006703 | 0.74 | AVPR1A (0.77) | AVPR1A | |
| SCHEMBL5215842 | 0.74 | AVPR1A (0.59) | GPR119LMNATHRBTP53GAA | |
| SCHEMBL15451333 | 0.73 | AVPR1A (0.46) | LMNAPOLBAVPR1AMAPT | |
| SCHEMBL3562965 | 0.73 | GPR119 (0.57) | GPR119LMNAPOLBTHRBTP53 | |
| SCHEMBL3557759 | 0.73 | GPR119 (0.57) | GPR119LMNAPOLBTHRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | GPR119 379/4885LMNA 1738/4885POLB 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.